Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer (Q61917935)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer |
clinical trial |
Statements
Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer (English)
0 references
July 2007
0 references
December 2014
0 references
32
0 references
18 year
0 references